Trials / Completed
CompletedNCT02825914
CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- University of Aarhus · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Casein glycomacropeptide (CGMP) has anti-inflammatory properties in experimental rodent colitis and using human in vitro inflammation models. Its use as a food ingredient has proven safe and with no influence on dietary intake. In a pilot study the investigators found, that orally administered CGMP seems to have a beneficial effect comparable to that of mesalazine in active distal ulcerative colitis. The investigators wish to evaluate the effects in a larger group of patients with active ulcerative colitis by studying the clinical effects and assessing the anti-inflammatory and microbiome modulating properties.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Casein glycomacropeptide (CGMP) | |
| DIETARY_SUPPLEMENT | Placebo |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2019-07-01
- Completion
- 2019-10-01
- First posted
- 2016-07-07
- Last updated
- 2020-04-07
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT02825914. Inclusion in this directory is not an endorsement.